Acromegaly – Pipeline Review, 2024

The excess secretion of growth hormone by pituitary gland leads to a hormonal disorder called acromegaly. The symptoms of acromegaly include overgrowth of bone and cartilage which may lead to arthritis. The symptoms include joint aches, skin tags, headaches, enlarged lips, impaired vision, etc. Global prevalence of acromegaly was found to be 60 per million populations in 2017 and an incidence rate of 3-4 per million populations per year.

Current treatment of acromegaly includes surgery, medication, and radiation. Drugs like octreotide and lanreotide are being used to reduce excess growth hormone secretion. Drugs like cabergoline and bromocriptine are being used to lower the excess levels of growth hormone. Additionally, pegvisomant a drug which acts by blocking the action of growth hormone, is also in use for the treatment of acromegaly.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for acromegaly. For instance; IONIS-GHR-LRx, which is being studied by Ionis Pharmaceuticals, Inc., is currently in phase-2 clinical trials for the study of safety, tolerability, and efficacy of IONIS-GHR-LRx patients with acromegaly.

At present around 70% of the pipeline candidates for acromegaly are in the phase-3 and phase-4 stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Acromegaly – Pipeline Review, 2020’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Acromegaly. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acromegaly.

The report on ‘Acromegaly – Pipeline Review, 2020’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Acromegaly


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Acromegaly


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary